<DOC>
	<DOCNO>NCT00965289</DOCNO>
	<brief_summary>A prospective pilot trial propose patient DLBCL , IH high adjust IPI , age 60 y.o . This program consist 2 course high-dose R-CHOP-like regimen , follow course high-dose methotrexate cytarabin . For patient achieve least PR , ASCT start BEAM regimen .</brief_summary>
	<brief_title>High-dose Chemotherapy With Rituximab Adults With Aggressive Large B-cell Lymphoma</brief_title>
	<detailed_description>Superiority HDT autologous stem cell transplantation ( ASCT ) upfront treatment poor-risk DLBCL remain option intermediate-high ( IH ) high IPI young adult . We update result prospective trial Goelams 074 evaluate long-term efficacy toxicity 42 patient underwent HDT ASCT .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age 18 60 y.o Aggressive Large BCell Lymphoma ( CD20+ ) Ann Arbor stage III , IV IH high adjust IPI sign inform consent Age &lt; 18 ou &gt; 60 y.o type lymphoma serology VIH + neoplasms apart basal cell carcinoma situ carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Aggressive large B-cell lymphoma ( DLBCL )</keyword>
	<keyword>Intensive chemotherapy</keyword>
	<keyword>Rituximab</keyword>
	<keyword>ASCT</keyword>
</DOC>